Literature DB >> 1511466

Cardiac sympathetic nervous activity during myocardial ischemia, reperfusion and ventricular fibrillation in the dog--effects of intravenous lidocaine.

I Aidonidis1, J Brachmann, H Seller, K Demowsky, J Czachurski, W Kübler.   

Abstract

In 12 open-chest dogs, cardiac sympathetic nervous activity (CSNA) was recorded before and after occlusion of the left anterior descending coronary artery as well as during reperfusion and ventricular fibrillation (VF). In 7 control animals, CSNA did not significantly differ from preocclusion levels when determined 20 min after occlusion (+3.5 +/- 1.5%, mean +/- SEM) and up to 15 min following reperfusion (+1.5 +/- 0.6%). However, VF was associated with a potential increase in CSNA by 106 +/- 15.5% (p less than 0.001). The effect of lidocaine (6 mg/kg) on cardiac sympathetic tone was examined in 5 additional animals. Lidocaine reduced control CSNA by 23 +/- 4.7% (p less than 0.001); subsequent ischemia and reperfusion did not substantially change the level of preocclusion activity. CSNA decreased significantly also during VF (52 +/- 4.2%, p less than 0.001). In conclusion, efferent CSNA was slightly altered in the course of acute myocardial ischemia and reperfusion, but significantly increased during VF. Lidocaine produced marked attenuation of CSNA in anesthetized dogs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1511466     DOI: 10.1159/000175003

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  2 in total

1.  Effects of lidocaine on isolated, blood-perfused ventricular contractility in the dog.

Authors:  M Tsuboi; S Chiba
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

2.  Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion.

Authors:  I Aidonidis; J Brachmann; I Rizos; A Zacharoulis; I Stavridis; P Toutouzas; W Kübler
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.